EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 6 Issue 2 2024

Emerging Biomarkers for Early Detection of Type 1 Diabetes in Pediatric Populations

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Type 1 diabetes (T1D) is a chronic autoimmune disease that results in the destruction of pancreatic beta cells, leading to lifelong dependence on insulin therapy. Early detection of T1D, particularly before the onset of clinical symptoms, is crucial for implementing preventative strategies and improving long-term outcomes. This review explores emerging biomarkers for early detection of T1D in pediatric populations, focusing on autoantibodies, genetic markers, and environmental factors. Autoantibodies targeting pancreatic islet antigens remain the most established biomarkers for T1D risk, while genetic profiling offers further insight into individual susceptibility. Early detection offers significant clinical benefits, including the opportunity for early interventions that could delay or even prevent the disease, as well as more personalized and effective management strategies. The combination of multiple biomarkers, advanced technologies, and personalized medicine approaches will likely provide the most reliable method for early T1D detection and risk prediction. While challenges remain in translating these biomarkers into clinical practice, continued research holds the potential to enhance early detection and pave the way for personalized prevention strategies in children at risk for T1D. This review used peer-reviewed information from PubMed and Scopus, published in the last decade.

Keywords: Type 1 diabetes, Biomarkers, Pediatric populations, Autoantibodies, Beta cells

INTRODUCTION

Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the progressive destruction of insulin-producing beta cells in the pancreas. This process leads to absolute insulin deficiency and requires lifelong insulin therapy for affected individuals [1–3]. While the clinical onset of T1D is often marked by symptoms of hyperglycemia, such as polyuria, polydipsia, and weight loss, by the time these symptoms appear, a significant portion of beta cell function has already been lost [4, 5]. This late-stage presentation highlights the critical need for early detection to prevent or delay disease progression, potentially through interventions that preserve beta cell function or modulate the autoimmune response.

Emerging research has focused on identifying biomarkers that can detect T1D long before the clinical onset, offering the possibility of early diagnosis and targeted therapeutic approaches. Early detection of at-risk individuals—particularly in pediatric populations—would allow for timely interventions, including lifestyle modifications, immunotherapy, or other preventive measures, which could alter the disease trajectory [6]. Recent advances have unveiled a range of promising biomarkers, including autoantibodies, genetic markers, gut microbiota profiles, and multi-omics data, that could help identify children at high risk of developing T1D [7]. Autoantibodies against pancreatic islet antigens have long been recognized as reliable indicators of T1D risk, often appearing years before the clinical manifestation of the disease [8]. Similarly, genetic risk factors, particularly those related to the human leukocyte antigen (HLA) system, have shown strong associations with T1D susceptibility [9]. Additionally, the growing understanding of the gut microbiome's role in immune modulation has opened new avenues for identifying potential biomarkers for early T1D detection [10]. Despite significant progress in these areas, challenges remain in translating these biomarkers into clinical practice. Variability in biomarker expression, difficulties in early-stage prediction, and the need for validation in diverse pediatric populations are ongoing hurdles. Nonetheless, the integration of biomarkers into early diagnostic tools holds great promise for improving the early identification of T1D and enhancing personalized strategies for prevention and treatment. This review aims to provide an overview of the most recent developments in the search for early biomarkers for T1D in pediatric populations, highlighting their potential and addressing the challenges that lie ahead in achieving practical clinical applications.

METHODOLOGY

This review article examines the development of emerging biomarkers for early detection of Type 1 Diabetes in pediatric populations. The methodology involved a thorough search of scientific literature published between 2015 and 2024, focusing on pediatric T1D biomarkers such as genetic, immunological, metabolic, and environmental markers. The selection criteria included studies relevant to early detection, identification of biomarkers, and their clinical or preclinical impact. Key information was extracted from selected articles, including biomarker type, detection methods, patient demographics, clinical outcomes, and potential clinical application. Biomarkers were categorized into genetic, autoantibody, and environmental markers, with special attention given to recent advancements in the field. Quality assessment was performed, ensuring high-quality, peer-reviewed sources from PubMed and Scopus, were included.

Autoantibodies as Early Biomarkers of Type 1 Diabetes

The identification of autoantibodies targeting pancreatic islet antigens has been one of the most significant advances in early detection of Type 1 Diabetes (T1D). These autoantibodies are markers of an autoimmune response directed against beta cells in the pancreas and often appear years before the clinical symptoms of the disease. Their presence serves as an early warning sign of T1D, allowing for the identification of individuals who are at high risk of developing the disease [11]. Common autoantibodies associated with T1D include:

i. ***Insulin Autoantibodies (IAA):*** One of the first autoantibodies to appear in some individuals, IAA targets insulin, which is produced by beta cells in the pancreas. It is often detected in pre-diabetic stages, particularly in children with a family history of T1D [12].

ii. ***Glutamic Acid Decarboxylase Autoantibodies (GAD65)***: The GAD65 enzyme is critical for proper beta cell function, and autoantibodies against GAD65 are found in majority of T1D patients. The presence of GAD65 antibodies in pediatric populations can predict the progression to T1D, particularly when multiple autoantibodies are present [13].

iii. ***Islet Cell Autoantibodies (ICA):*** These antibodies target the islet cells in the pancreas, where insulin is produced. They are often detected in early stages of T1D, making them useful for identifying children at risk [8].

iv. ***Tyrosine Phosphatase-related Islet Antigen 2 (IA-2A):*** IA-2A antibodies target the IA-2 protein, which plays a crucial role in insulin secretion. The presence of IA-2A is considered a reliable marker of T1D progression, especially when it occurs alongside other islet autoantibodies [14].

v. ***Zinc Transporter 8 Autoantibodies (ZnT8):*** This is a newer biomarker for T1D, and its presence has been shown to correlate with the risk of developing the disease, particularly in children [15]. ZnT8 antibodies are often detected in individuals who are genetically predisposed to T1D.

Genetic Markers of Type 1 Diabetes

Genetic factors play a critical role in the development of Type 1 Diabetes (T1D), with heritability estimates ranging from 50% to 80% [16, 17]. The genetic susceptibility to T1D is complex, involving multiple genes that interact with environmental triggers. Among the most important genetic markers for T1D are those located in the human leukocyte antigen (HLA) region, specifically the HLA class II genes, which are involved in immune system regulation [9].

i. ***HLA-DR3** and **HLA-DR4**:* These alleles are the most strongly associated with an increased risk of T1D. Children who inherit these alleles, particularly when both are present, have a higher likelihood of developing the disease. HLA-DR3/DR4 heterozygosity is a well-established risk factor for T1D, and it is considered one of the first genetic markers to be tested in children at risk [18].

ii. ***HLA-DQ2** and **HLA-DQ8**:* These alleles are also linked to T1D, particularly in children with a family history of autoimmune diseases. The presence of these markers is often used to assess genetic susceptibility in at-risk children [19].

While HLA alleles account for a substantial proportion of genetic risk for T1D, they are not sufficient to predict disease onset on their own. In fact, many individuals carrying high-risk HLA alleles never develop T1D, suggesting that additional genetic and environmental factors play a role in disease pathogenesis. Recent research has identified numerous non-HLA genetic markers associated with T1D, including variants in the INS gene (which encodes insulin), PTPN22 (a gene involved in immune regulation), and IL2RA (related to T-cell function) [20]. These variants contribute to a small but significant increase in risk, and their combined effects may improve genetic risk prediction models. The advent of genetic risk scores (GRS), which aggregate the effects of multiple genetic variants, has further refined risk prediction in children. GRS can estimate an individual's genetic predisposition to T1D more accurately than individual gene variants [21]. The use of GRS, in combination with autoantibody screening and other risk factors, could help identify children at high risk of developing T1D before the onset of clinical symptoms. However, genetic testing alone is not sufficient for early detection due to the complexity of T1D's pathogenesis. Although genetic risk factors can help identify at-risk children, they must be interpreted in conjunction with other biomarkers, such as autoantibodies and environmental exposures, to improve predictive accuracy.

Environmental Factors and Their Role in Early Detection of Type 1 Diabetes

Environmental factors, such as diet, infections, and toxins, have long been suspected to play a role in the development of Type 1 Diabetes (T1D). While genetics provide the foundational risk, environmental triggers are often believed to initiate the autoimmune process that leads to beta-cell destruction [22]. These factors are especially important in pediatric populations, where the onset of T1D typically occurs after early-life exposures. A better understanding of the role of environmental factors in the early stages of T1D can offer new avenues for early detection and preventive interventions.

Several environmental factors have been identified as potential triggers for T1D, including:

1. **Infections**: Certain viral infections, particularly enteroviruses like coxsackievirus B, have been linked to an increased risk of T1D. These viruses can infect pancreatic beta cells and trigger an immune response that leads to beta-cell destruction. While viral infections alone do not cause T1D, they can act as an environmental trigger in genetically susceptible individuals [23]. Identifying specific viruses that are associated with T1D onset could provide an early biomarker for the disease.
2. **Dietary Factors**: The introduction of solid foods, particularly cow's milk, gluten, and certain proteins, during infancy has been suggested as a potential environmental factor that influences the development of T1D. Research has shown that early exposure to these dietary components may alter the immune system's response, potentially initiating an autoimmune reaction against pancreatic beta cells [24]. The timing and type of food introduced during infancy could, therefore, serve as an early indicator of increased risk.
3. **Vitamin D Deficiency**: Several studies have suggested that a deficiency in vitamin D during early childhood may increase the risk of T1D. Vitamin D plays a crucial role in immune system regulation, and its deficiency may lead to dysregulated immune responses, contributing to the development of autoimmunity [25]. Low vitamin D levels may serve as an early biomarker for children at increased risk of T1D, particularly in regions with limited sunlight exposure or poor dietary intake [26].
4. **Hygiene Hypothesis and Microbial Exposure**: The hygiene hypothesis suggests that reduced exposure to microbes in early childhood can lead to an increased risk of autoimmune diseases like T1D. The lack of exposure to a diverse range of pathogens and microbes may impair immune system development, potentially contributing to autoimmune diseases. Conversely, early exposure to certain bacteria, particularly those found in rural environments, has been associated with a reduced risk of T1D [27]. The role of early-life microbial exposures could therefore be considered in early detection strategies, especially in regions with high levels of hygiene.
5. **Pollution and Toxins**: Exposure to environmental pollutants, such as pesticides, industrial chemicals, and air pollution, has been associated with an increased risk of autoimmune diseases, including T1D [28]. These pollutants can disrupt endocrine function, alter immune system responses, and potentially trigger autoimmune reactions. Children living in areas with high levels of environmental toxins may therefore be at higher risk of developing T1D [29]. Identifying these environmental factors could help pinpoint children at increased risk and allow for targeted preventive measures.

Clinical Implications of Early Detection of Type 1 Diabetes in Pediatrics

The early detection of Type 1 Diabetes (T1D) in pediatric populations has profound clinical implications. Identifying children at high risk of developing T1D before the onset of clinical symptoms can open up opportunities for early interventions that may delay or even prevent the disease's progression. Additionally, early detection allows for better management of the disease and improved long-term outcomes, including reducing the risk of complications associated with T1D [30]. Several clinical implications of early detection include:

1. **Early Interventions**: Identifying children at high risk of T1D could lead to early interventions aimed at preventing or delaying disease onset. Immunomodulatory treatments, such as the use of immune-suppressive drugs, anti-inflammatory therapies, or tolerogenic vaccines, could be administered before beta-cell destruction occurs, potentially preserving insulin production and delaying the need for insulin therapy [31]. Early interventions could also focus on lifestyle changes, such as dietary modifications or the use of probiotics, to influence immune function and prevent autoimmunity.
2. **Personalized Medicine**: Early detection provides an opportunity for personalized medicine, where interventions are tailored to the individual based on their genetic, immunological, and environmental risk

factors. This approach can optimize treatment and minimize unnecessary interventions. For instance, children with a specific genetic profile may benefit from early monitoring or specific immunomodulatory treatments, while others may not require such interventions [32].

3. **Improved Management and Monitoring**: Early identification of children at risk allows for more frequent and intensive monitoring of their health status. Regular screening for autoantibodies, genetic markers, and metabolic changes can help detect early signs of disease progression. Additionally, continuous glucose monitoring (CGM) and other advanced technologies can be used to track glucose levels and insulin requirements more effectively, reducing the risk of complications later in life [30].
4. **Psychosocial Benefits**: Early detection of T1D in pediatric populations can help families better prepare for the disease and mitigate the emotional and psychological burden associated with its onset. By identifying children at risk, parents can gain insight into potential treatment options and lifestyle changes, reducing anxiety and providing a clearer path for managing the disease [33]. Early diagnosis also allows for more time to adjust to the emotional and practical challenges of living with diabetes [17].
5. **Improved Long-Term Outcomes**: Early detection and intervention in T1D can significantly improve long-term outcomes. Studies have shown that preserving residual beta-cell function, even in the early stages of the disease, can reduce the need for insulin therapy and decrease the risk of complications such as diabetic retinopathy, neuropathy, and cardiovascular disease [34]. Early management also improves metabolic control, which is essential for preventing long-term complications.

CONCLUSION

The early detection of Type 1 Diabetes (T1D) in pediatric populations holds the potential to revolutionize the way the disease is managed and prevented. Early detection offers significant clinical benefits, including the opportunity for early interventions that could delay or even prevent the disease, as well as more personalized and effective management strategies. However, many challenges remain, including the need for more robust, large-scale studies to validate these biomarkers and determine their practical utility in clinical settings. The combination of multiple biomarkers, advanced technologies, and personalized medicine approaches will likely provide the most reliable method for early T1D detection and risk prediction. As research continues to progress, the integration of these tools into clinical practice will help identify children at risk of developing T1D, leading to better outcomes and a future where the disease can be managed or prevented before it even starts.

REFERENCES

1. Agbafor, K., Onuoha, S., Ominyi, M., Orinya, O., Ezeani, N.: Antidiabetic, Hypolipidemic and Antiathrogenic Properties of Leaf Extracts of Ageratum conyzoides in Streptozotocin-Induced diabetic rats. 4, 816–8247706 (2015)
2. Alum, E., P.C., U., Obeagu, E., Aja, P., Ugwu, C., Okon, M.: Nutritional Care in Diabetes Mellitus: A Comprehensive Guide. 11, 16–15 (2023). https://doi.org/10.58538/IJIAR/2057
3. Alum, E.U., Umoru, G.U., Uti, D.E., Aja, P.M., Ugwu, O.P., Orji, O.U., Nwali, B.U., Ezeani, N.N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect of Ethanol Leaf Extract of Datura Stramonium in Alloxan-Induced Diabetic Albino Rats. J. Chem. Soc. Niger. 47, (2022). https://doi.org/10.46602/jcsn.v47i5.819
4. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Aja, P.M., Obeagu, E.I., Onyeneke, E.C.: Ethanol root extract and fractions of Sphenocentrum jollyanum abrogate hyperglycaemia and low body weight in streptozotocin-induced diabetic Wistar albino rats. RPS Pharm. Pharmacol. Rep. 2, rqad010 (2023). https://doi.org/10.1093/rpsppr/rqad010
5. Uti, D.E., Igile, G.O., Omang, W.A., Umoru, G.U., Udeozor, P.A., Obeten, U.N., Ogbonna, O.N., Ibiam, U.A., Alum, E.U., Opotu, Ohunene, R., Chukwufumnanya, M.J., Oplekwu, R.I., A, W., Obio: Anti-Diabetic Potentials Of Vernonioside E Saponin; A Biochemical Study. NVEO - Nat. VOLATILES Essent. OILS J. NVEO. 14234–14254 (2021)
6. Chiang, J.L., Maahs, D.M., Garvey, K.C., Hood, K.K., Laffel, L.M., Weinzimer, S.A., Wolfsdorf, J.I., Schatz, D.: Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care. 41, 2026–2044 (2018). https://doi.org/10.2337/dci18-0023
7. Mănescu, M., Mănescu, I.B., Grama, A.: A Review of Stage 0 Biomarkers in Type 1 Diabetes: The Holy Grail of Early Detection and Prevention? J. Pers. Med. 14, 878 (2024). https://doi.org/10.3390/jpm14080878
8. Kawasaki, E.: Anti-Islet Autoantibodies in Type 1 Diabetes. Int. J. Mol. Sci. 24, 10012 (2023). https://doi.org/10.3390/ijms241210012
9. Sticht, J., Álvaro-Benito, M., Konigorski, S.: Type 1 Diabetes and the HLA Region: Genetic Association Besides Classical HLA Class II Genes. Front. Genet. 12, (2021). https://doi.org/10.3389/fgene.2021.683946

10. Ugwu, O.P.-C., Alum, E.U., Okon, M.B., Obeagu, E.I.: Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions. Medicine (Baltimore). 103, e38088 (2024). https://doi.org/10.1097/MD.0000000000038088
11. Ma, H., Murphy, C., Loscher, C.E., O'Kennedy, R.: Autoantibodies - enemies, and/or potential allies? Front. Immunol. 13, (2022). https://doi.org/10.3389/fimmu.2022.953726
12. Regnell, S.E., Lernmark, Å.: Early prediction of autoimmune (type 1) diabetes. Diabetologia. 60, 1370–1381 (2017). https://doi.org/10.1007/s00125-017-4308-1
13. Liimatainen, S., Honnorat, J., Pittock, S.J., McKeon, A., Manto, M., Radtke, J.R., Hampe, C.S., T1D Exchange Biobank: GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies. Orphanet J. Rare Dis. 13, 55 (2018). https://doi.org/10.1186/s13023-018-0787-5
14. Buzzetti, R., Spoletini, M., Zampetti, S., Campagna, G., Marandola, L., Panimolle, F., Dotta, F., Tiberti, C., NIRAD Study Group (NIRAD 8): Tyrosine phosphatase-related islet antigen 2(256-760) autoantibodies, the only marker of islet autoimmunity that increases by increasing the degree of BMI in obese subjects with type 2 diabetes. Diabetes Care. 38, 513–520 (2015). https://doi.org/10.2337/dc14-1638
15. Fakhfakh, R., Kmiha, S., Tahri, S., Feki, S., Zouidi, F., Abida, O., Hachicha, M., Kammoun, T., Masmoudi, H.: Autoantibodies to Zinc Transporter 8 and SLC30A8 Genotype in Type 1 Diabetes Childhood: A Pioneering Study in North Africa. J. Diabetes Res. 2022, 2539871 (2022). https://doi.org/10.1155/2022/2539871
16. Alum, E., P.C., U., Obeagu, E., Extension, K.P.: Beyond Pregnancy: Understanding the Long-Term Implications of Gestational Diabetes Mellitus. INOSR Sci. Res. 11, 63–71 (2024). https://doi.org/10.59298/INOSRSR/2024/1.1.16371
17. Alum, E., Ugwu, P.-C., Obeagu, E., Uti, D., Egba, S., Alum, B.: Managing the Dual Burden: Addressing Mental Health in Diabetes Care. 2, 1–9 (2024)
18. Noble, J.A.: Fifty years of HLA-associated type 1 diabetes risk: history, current knowledge, and future directions. Front. Immunol. 15, (2024). https://doi.org/10.3389/fimmu.2024.1457213
19. Zubkiewicz-Kucharska, A., Jamer, T., Chrzanowska, J., Akutko, K., Pytrus, T., Stawarski, A., Noczyńska, A.: Prevalence of haplotype DQ2/DQ8 and celiac disease in children with type 1 diabetes. Diabetol. Metab. Syndr. 14, 128 (2022). https://doi.org/10.1186/s13098-022-00897-8
20. Klak, M., Gomółka, M., Kowalska, P., Cichoń, J., Ambrożkiewicz, F., Serwańska-Świętek, M., Berman, A., Wszoła, M.: Type 1 diabetes: genes associated with disease development. Cent.-Eur. J. Immunol. 45, 439–453 (2020). https://doi.org/10.5114/ceji.2020.103386
21. Qu, H.-Q., Qu, J., Bradfield, J., Glessner, J., Chang, X., March, M., Mentch, F.D., Roizen, J.D., Connolly, J.J., Sleiman, P., Hakonarson, H.: Combined application of genetic and polygenic risk scores for type 1 diabetes risk prediction. Diabetes Obes. Metab. 23, 2001–2003 (2021). https://doi.org/10.1111/dom.14419
22. Aja, P., Igwenyi, I., P.C., U., Orji, O., Alum, E.: Evaluation of Anti-diabetic Effect and Liver Function Indices of Ethanol Extracts of Moringa oleifera and Cajanus cajan Leaves in Alloxan Induced Diabetic Albino Rats. 439–447 (2015). https://doi.org/10.5829/idosi.gv.2015.14.03.93129
23. Geravandi, S., Liu, H., Maedler, K.: Enteroviruses and T1D: Is It the Virus, the Genes or Both which Cause T1D. Microorganisms. 8, 1017 (2020). https://doi.org/10.3390/microorganisms8071017
24. Environmental Triggering of Type 1 Diabetes Autoimmunity - PubMed, https://pubmed.ncbi.nlm.nih.gov/35937815/
25. Alum, E.U., Aja, W., Ugwu, O.P.C., Obeagu, E.I., Okon, M.B.: Assessment of Vitamin Composition of Ethanol Leaf and Seed Extracts of Datura Stramonium. Avicenna J. Med. Biochem. 11, 92–97 (2023). https://doi.org/10.34172/ajmb.2023.2421
26. Daskalopoulou, M., Pylli, M., Giannakou, K.: Vitamin D Deficiency as a Possible Cause of Type 1 Diabetes in Children and Adolescents up to 15 Years Old: A Systematic Review. Rev. Diabet. Stud. RDS. 18, 58–67 (2022). https://doi.org/10.1900/RDS.2022.18.58
27. Stiemsma, L.T., Reynolds, L.A., Turvey, S.E., Finlay, B.B.: The hygiene hypothesis: current perspectives and future therapies. ImmunoTargets Ther. 4, 143–157 (2015). https://doi.org/10.2147/ITT.S61528
28. Alum, E.U.: Highlights of Heavy Metals: Molecular Toxicity Mechanisms, Exposure Dynamics, and Environmental Presence. IAA J. Appl. Sci. 10, 8–19 (2023). https://doi.org/10.59298/IAAJAS/2023/4.2.3222
29. Rewers, M., Ludvigsson, J.: Environmental risk factors for type 1 diabetes. Lancet Lond. Engl. 387, 2340–2348 (2016). https://doi.org/10.1016/S0140-6736(16)30507-4
30. Obeagu, E.I., Ugwu, O.P.-C., Alum, U.: Poor Glycaemic Control among Diabetic Patients: A Review on Associated Factors. (2023)

31. Simmons, K.M., Gottlieb, P.A., Michels, A.W.: Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes. Curr. Diab. Rep. 16, 97 (2016). https://doi.org/10.1007/s11892-016-0793-8
32. Di Meco, A., Vassar, R.: Early detection and personalized medicine: Future strategies against Alzheimer's disease. Prog. Mol. Biol. Transl. Sci. 177, 157–173 (2021). https://doi.org/10.1016/bs.pmbts.2020.10.002
33. Kalra, S., Jena, B.N., Yeravdekar, R.: Emotional and Psychological Needs of People with Diabetes. Indian J. Endocrinol. Metab. 22, 696 (2018). https://doi.org/10.4103/ijem.IJEM_579_17
34. Ipp, E.: Diabetic Retinopathy and Insulin Insufficiency: Beta Cell Replacement as a Strategy to Prevent Blindness. Front. Endocrinol. 12, (2021). https://doi.org/10.3389/fendo.2021.734360

CITE AS: Kato Jumba K. (2024). Emerging Biomarkers for Early Detection of Type 1 Diabetes in Pediatric Populations. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 6(2):31-36.